Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Revenue:
Product sales	$ 3,843,787	$ 5,246,159	$ 5,941,254
Royalties	1,603,371	2,974,365	4,991,266
Licensing revenue	10,250,740	1,300,763	1,253,260
Development fees and other revenues	3,517,440	811,992	545,788
Tarsa revenue	1,293,008	1,006,935	60,270
	20,508,346	11,340,214	12,791,838
Operating Expenses:
Cost of goods sold	1,551,624	2,608,083	2,171,231
Research and development	9,015,749	6,428,041	12,350,796
General and administrative	8,887,010	7,685,039	8,937,683
Unallocated facility expenses	3,345,971	3,105,989	1,711,642
Inventory reserve		716,989
Loss on sale of patents	824,241
Severance expense - Levys	349,980	1,120,000
	23,974,575	21,664,141	25,171,352
Operating Loss	(3,466,229)	(10,323,927)	(12,379,514)
Other income (expense):
Gain (loss) on change in fair value of embedded conversion feature	10,390,000	(1,670,000)
Loss on extinguishment of debt		(14,381,239)
Qualifying therapeutic discovery grant		977,917
Gain on technology license to Tarsa - net			5,685,530
Interest and other income	58,535	85,546	133,581
Interest expense	(10,483,866)	(8,038,525)	(4,862,319)
Gain (loss) from investment in former China joint venture	(1,375,925)	115,774	95,378
Loss from investment in Tarsa	(2,819,143)		(2,119,450)
Loss before income taxes	(7,696,628)	(33,234,454)	(13,446,794)
Income tax benefit – principally from sale of New Jersey tax benefits in 2011 and 2010	601,070	700,503	67,115
Net loss	$ (7,095,558)	$ (32,533,951)	$ (13,379,679)
Net loss per share (in Dollars per share)	$ (0.08)	$ (0.35)	$ (0.15)
Weighted average number of shares outstanding – basic and diluted (in Shares)	93,181,384	91,961,673	90,662,089